Tag Archives: Venture Capital

Driving Innovation in Breast Cancer: Startup Challenge

Driving Innovation

The Avon Foundation (AF), National Institutes of Health National Cancer Institute (NCI) and Center for Advancing Innovation (CAI) have partnered to launch a “first of a kind” Business Plan and Start-Up Challenge for Breast Cancer (BC) inventions that have high commercial viability and are important to public health. This challenge will accelerate the commercialization of Federal agency and AF grantee BC inventions, spur economic growth, and provide Universities a platform to further develop their entrepreneurship learning portfolio. Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

Venture Capital Trends

Venture Capital Trends

With industry data and numbers, results are always a mixed bag, says David Thomas, BIO’s Director of Industry Research & Analysis – and the latest on venture capital trends is no exception. In the U.S., biotech VC funding is flat, and start-up money is drying up. According to the National Venture Capital Association (NCVA), U.S. VC funding for biotech fell to $4.1 billion in 2012 (figure 1). This 17% drop was greater than the 10% Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO-Europe Spring Opening Remarks

Chart

BIO’s own David Thomas, Director of Industry Research, delivered opening remarks at the BIO-Europe Spring conference in Barcelona yesterday. His slides provide a snapshot of the biotech industry’s performance and highlight emerging trends in venture exits: IPOs and M&A. Takeaways from his talk include breakouts on multiple fronts for the industry: FDA approvals at highs not seen since the 1990s Orphan designation approvals at all-time highs IPOs starting to show signs of life in 2012 Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Biotech Hall of Fame: Interview with Biotech’s First Investment Banker

Biotech Hall of Fame

Earlier this week, I had the opportunity to discuss biotech’s storied history with Fred Frank, one of the industry’s greatest luminaries, on what we can learn from the past to help shape the future. Fred Frank, formerly Vice Chairman of both Lehman Brothers Inc. and Peter J. Solomon Company, recently became Vice Chairman of Burrill & Company and Chairman of Burrill Securities, the broker dealer arm of Burrill & Company. He was the first life Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Big Ventures

Stock Ticker

It is rare to see triple digit millions in private financing rounds, but it does happen once or twice a year on average. In the headlines last week, was the largest triple digit VC round in years – the $160M in venture capital funding for Intarcia. With the simultaneous debt financing of $50M, the total funding round was $210M. Behind the deal were existing investors New Enterprise Associates, New Leaf Venture Partners and Venrock, plus Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,